Prognostic value of lymphocyte-to-monocyte ratio among Asian lung cancer patients: a systematic review and meta-analysis

Wen, Li; Ma, Guangzhi; Wu, Qiang; Deng, Yunfu; Liu, Ya; Wang, Jing

doi:10.18632/oncotarget.20574

Cited by 25 publications

(42 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four, the optimal cutoff values of the NLR, PLR, and LMR in our study were 2.12, 92.9, and 4.57, respectively. In previous studies, their critical values ranged from 2.5 to 5, 106 to 300, and 2.62 to 4.56, respectively; therefore, the critical values in the current study may only be appropriate to the population of our center. If physicians from other medical centers attempt to apply this prognostic scoring system, we suggest that they perform their own analysis to obtain the local cutoff values that are appropriate to the specific patient population.…”

Section: Discussionmentioning

confidence: 84%

“…The association between blood cell counts or their ratios with lung cancer prognosis has been explored . Yin et al conducted a meta‐analysis including 2734 patients from 14 studies and reported that a high NLR was a predictor of poor OS in lung cancer (HR 1.192, 95% CI 1.061–1.399; P heterogeneity = 0.003) .…”

Section: Discussionmentioning

confidence: 99%

“…Zhang et al also conducted a meta‐analysis of 2889 patients from 12 studies and reported that NSCLC patients with an elevated PLR were more likely to have shorter OS after therapy (HR 1.492, 95% CI 1.231–1.807; P < 0.001) . Furthermore, in their meta‐analysis including 3954 patients from eight studies, Li et al demonstrated that a low LMR was significantly associated with poorer OS (HR 1.651, 95% CI 1.306–2.086, P < 0.001) and progression‐free survival (PFS, HR 1.431, 95% CI 1.294–1.582, P < 0.001) . However, our results indicated that none of the three ratios were independent prognostic factors for OS of NSCLC, thus a larger sample is required to verify their value for predicting NSCLC prognosis.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, it would be very helpful for clinicians to develop and adjust treatment The association between blood cell counts or their ratios with lung cancer prognosis has been explored. [23][24][25] Yin et al conducted a meta-analysis including 2734 patients from 14 studies and reported that a high NLR was a predictor of poor OS in lung cancer (HR 1.192, 95% CI 1.061-1.399; P heterogeneity = 0.003). 23 Zhang et al also conducted a meta-analysis of 2889 patients from 12 studies and reported that NSCLC patients with an elevated PLR were more likely to have shorter OS after therapy (HR 1.492, 95% CI 1.231-1.807; P < 0.001).…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Prognostic value of a novel scoring system using inflammatory response biomarkers in non‐small cell lung cancer: A retrospective study

Wang

et al. 2019

Thoracic Cancer

View full text Add to dashboard Cite

Background The neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), and lymphocyte‐to‐monocyte ratio (LMR) are reported to show a strong correlation with prognosis in patients with non‐small cell lung cancer (NSCLC). We aimed to describe a novel scoring system combining these ratios, termed the inflammatory response biomarker (IRB) score, and test its prognostic value in NSCLC. Methods The data of 261 NSCLC patients who underwent thoracoscopic radical resection in a single center were retrospectively reviewed. The IRB score was defined as follows: a high NLR (> 2.12), a high PLR (92.9), and a low LMR (< 4.57) were each scored as 1; the opposite values were scored as 0. The individual scores were added to produce the IRB score (range: 0–3). Results Multivariate analyses indicated that high tumor node metastasis (TNM) stage (hazard ratio [HR] 2.721, 95% confidence interval [CI] 1.597–4.989; P < 0.001) and an IRB score ≥ 2 (HR 2.696, 95% CI 1.506–4.826; P = 0.001) were independent prognostic factors for poor overall survival. Furthermore, smoking history (HR 2.953, 95% CI 1.086–8.026; P = 0.034), high TNM stage (HR 3.108, 95% CI 1.911–5.056; P < 0.001), and IRB score ≥ 2 (HR = 2.316, 95% CI: 1.389–3.861; P = 0.001) were demonstrated to be independent prognostic factors for poor disease‐free survival. Conclusion The novel scoring system combining NLR, PLR, and LMR was an independent prognostic factor in NSCLC patients undergoing thoracoscopic radical resection and was superior to these ratios alone for predicting prognosis.

show abstract

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic value of a novel scoring system using inflammatory response biomarkers in non‐small cell lung cancer: A retrospective study

Wang

et al. 2019

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…The lymphocyte-to-monocyte ratio (LMR) has been reported to reflect host immunity in various malignancies. [11][12][13][14] Peripheral lymphocytes represent tumour-related lymphocytes, while peripheral monocytes represent TAMs. Therefore, low and high LMRs indicate weak and strong immune responses against tumours, respectively.…”

Section: Introductionmentioning

confidence: 99%

Prognostic role of the lymphocyte‐to‐monocyte ratio for clinical outcomes of patients with progressive radioiodine‐refractory differentiated thyroid carcinoma treated by sorafenib

Ahn

Song

Kim

et al. 2019

Clinical Endocrinology

View full text Add to dashboard Cite

Objectives:The lymphocyte-to-monocyte ratio (LMR) reflects the status of tumourinfiltrating immune cells and host immunity. The LMR has been reported as a prognostic marker in various cancers. The present study evaluated the role of the LMR as a prognostic marker in patients with progressive radioiodine-refractory (RAIR) differentiated thyroid carcinoma (DTC). Design: Retrospective cohort study.Patients: Forty patients with progressive RAIR DTC who were treated by sorafenib with available baseline complete blood cell count data. Measurements:We assessed the response rate, progression-free survival (PFS) and overall survival (OS). Results:The patients were divided into low and high LMR groups based on their baseline LMRs (<4, n = 22, 55% and ≥4, n = 18, 45%, respectively). There were no significant differences in baseline characteristics between the groups. The OS curves differed significantly based on the LMR. The median OS of the low LMR group was 24.3 months and that of the high LMR group was not reached until the end of observation period (P = .015). The PFS curves and median PFS also differed significantly based on the LMR values (P = .019). In multivariate analysis, low LMR was an independent risk factor for all-cause mortality in patients with progressive RAIR DTC (hazard ratio, 2.64; 95% confidence interval: 1.04-6.72, P = .041). Conclusion:A low LMR was associated with poor response rate, PFS and OS in patients with progressive RAIR DTC treated with sorafenib. Thus, LMR could be a simple prognostic biomarker in patients with progressive RAIR DTC. K E Y W O R D Sdifferentiated thyroid carcinoma, immune system, lymphocyte, monocytes, sorafenib

show abstract

Improvement of Mortality Prognostication in Patients With Epidermal Necrolysis

2022

View full text Add to dashboard Cite

IMPORTANCEEpidermal necrolysis is a severe cutaneous adverse reaction in which severe systemic inflammation results in extensive epithelial keratinocyte necrosis. The most commonly used prognostic score in epidermal necrolysis, the Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN), was recently found to overestimate mortality in contemporary cohorts. Identification of independent prognostic markers may help to stratify risk more accurately.OBJECTIVE This study evaluates the association between novel inflammatory markers and in-hospital mortality in patients with epidermal necrolysis to study the incremental prognostic value of these markers in combination with SCORTEN. DESIGN, SETTING, AND PARTICIPANTSA retrospective cohort study was conducted over a 17-year period from 2003 to 2019. Patients were enrolled from Singapore General Hospital, the national referral center for epidermal necrolysis. A total of 196 patients with epidermal necrolysis were recruited, 4 (2%) of whom were excluded owing to incomplete data. MAIN OUTCOMES AND MEASURESThe main outcome assessed was the in-hospital mortality rate. Discrimination and calibration of risk scores were assessed using the area under the receiver operating characteristic curve (AUC) and calibration plot, respectively. Evaluation of the incremental prognostic value of these markers was done by comparing the AUC between the old and new risk score, and the use of net reclassification improvement (NRI) and integrated discrimination improvement (IDI). RESULTS Among 192 total patients (median [IQR] age 56 years; 114 [59.4%] women), there were 43 (22.4%) who did not survive to discharge. Of the novel inflammatory markers, only red cell distribution width to hemoglobin ratio was significant in predicting in-hospital mortality (odds ratio [OR] 3.55; 95% CI, 1.76-7.16; P < .001) after adjusting for SCORTEN. The RDW/Hb as applied in 4 risk groups showed similar discrimination to SCORTEN (AUC [95% CI]: RDW/Hb in 4 groups, 0.76 [0.69-0.84], vs SCORTEN, 0.78 [0.70-0.85], P = .89). When RDW/Hb was added to SCORTEN, the composite score Re-SCORTEN showed significantly better discrimination than SCORTEN alone (AUC [95% CI]: vs SCORTEN,], P = .02). The overall NRI was 0.94 (95% CI, 0.68-1.20), P < .001. The IDI was 0.06 (95% CI 0.03-0.08), P < .001. Re-SCORTEN showed good calibration based on the calibration plot. CONCLUSIONS AND RELEVANCEIn this cohort of patients, RDW/Hb, an inexpensive and readily available marker, showed similar predictive accuracy with SCORTEN. Furthermore, when used in combination with SCORTEN, it also helped augment prognostic ability.

show abstract

Prognostic value of lymphocyte-to-monocyte ratio among Asian lung cancer patients: a systematic review and meta-analysis

Cited by 25 publications

References 37 publications

Prognostic value of a novel scoring system using inflammatory response biomarkers in non‐small cell lung cancer: A retrospective study

Prognostic value of a novel scoring system using inflammatory response biomarkers in non‐small cell lung cancer: A retrospective study

Prognostic role of the lymphocyte‐to‐monocyte ratio for clinical outcomes of patients with progressive radioiodine‐refractory differentiated thyroid carcinoma treated by sorafenib

Improvement of Mortality Prognostication in Patients With Epidermal Necrolysis

Contact Info

Product

Resources

About